Showing 1021-1030 of 1211 results for "".
- Alcon to Showcase Innovations for Eye Care Practice Success at 2023 Optometry’s Meetinghttps://modernod.com/news/alcon-to-showcase-innovations-for-eye-care-practice-success-at-2023-optometrys-meeting/2481682/Alcon will showcase innovations from advances in the reusable lens space to digital offerings at Optometry’s Meeting, the American Optometric Association (AOA) annual conference taking place June 21-24 in Washington, D.C. Through interactive events, Q&A’s, live demonstrations, and
- Bausch + Lomb Announces New Scientific Data and Analyses Featuring Consumer, Vision Care and Pharmaceuticals Will Be Presented During Optometry's Meetinghttps://modernod.com/news/bausch-lomb-announces-new-scientific-data-and-analyses-featuring-consumer-vision-care-and-pharmaceuticals-will-be-presented-during-optometrys-meeting/2481662/Bausch + Lomb announced that researchers will present the results of 11 scientific poster presentations involving the company’s consumer, vision care and pharmaceutical products during the American Optometric Association (AOA) Optometry’s Meeting e-posters virtual event, which is taki
- New Data Published from Phase 3 N-MOmentum Trial of Horizon's Uplinzahttps://modernod.com/news/new-data-from-phase-3-n-momentum-trial-of-horizons-uplinza-published/2481660/Horizon Therapeutics announced the publication of new data from the Phase 3 N-MOmentum pivotal trial of Uplinza. The data offer insights on serum biomarkers that signal acute attacks and disability worsening associated with NMOSD and illustrate the role of Uplinza in reducing these biom
- Aviceda Announces Dosing of First Patient With AVD-104, a Novel Glyco-Mimetic Nanoparticle for the Treatment of GAhttps://modernod.com/news/aviceda-announces-dosing-of-first-patient-with-avd-104-a-novel-glyco-mimetic-nanoparticle-for-the-treatment-of-ga/2481647/Aviceda Therapeutics announced the dosing of its first patient with AVD-104 in its phase 2 SIGLEC trial by Ashkan Abbey, MD, of Texas Retina Associates in Dallas. This lead intravitreal asset is a novel glycan-coated nanoparticle, supported by a uniquely strong preclinical in
- NEI Explores Potential Impacts of Climate Change on Eye Healthhttps://modernod.com/news/nei-explores-potential-impacts-of-climate-change-on-eye-health/2481635/The National Eye Institute (NEI) convened a panel of experts on April 26, 2023, at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to discuss teye health care needs of the future, including the potential effects of a changing climate on eye health a
- Salvat Laboratories Presents Phase 3 Clinical Trials Results of Clobetasol Nanoemulsion for Treating Inflammation and Pain After Ocular Surgeryhttps://modernod.com/news/salvat-laboratories-presents-phase-3-clinical-trials-results-of-clobetasol-nanoemulsion-for-treating-inflammation-and-pain-after-ocular-surgery/2481604/Salvat Laboratories announced the results of phase 3 clinical trials of its ophthalmic corticosteroid at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in New Orleans. The studies’ global coordinator, Andrew Schwartz, MD, presented a poster outlinin
- RG6501 (OpRegen) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in GAhttps://modernod.com/news/rg6501-opregen-phase-12a-clinical-results-support-the-potential-for-opregen-to-slow-stop-or-reverse-disease-progression-in-ga/2481569/Lineage Cell Therapeutics announced that results from imaging analyses of structural changes and visual data from a phase 1/2a clinical study of RG6501 (OpRegen), were presented at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2023). The presentation
- New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023https://modernod.com/news/new-data-on-two-nicoxs-assets-ncx-470-and-ncx-1728-presented-at-arvo-2023/2481567/Nicox announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2023 being held April 23-27, 2023 in New Orleans. Poster title: NCX 470, a nitric oxide (NO)-donating&
- Atsena Therapeutics Announces Positive 6-month Data from Ongoing Phase 1/2 Clinical Trial of ATSN-101 in Patients with LCA1https://modernod.com/news/atsena-therapeutics-announces-positive-6-month-data-from-ongoing-phase-12-clinical-trial-of-atsn-101-in-patients-with-lca1/2481563/Atsena Therapeutics announced positive 6-month safety and efficacy data from the ongoing phase 1/2 clinical trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). The data were presented by Chris
- Iveric Bio Announces New Functional Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trialshttps://modernod.com/news/iveric-bio-announces-new-functional-vision-loss-reduction-data-from-avacincaptad-pegol-gather-trials/2481557/Iveric bio announced new findings from exploratory analyses of data for avacincaptad pegol (ACP), which were presented at the 2023 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) in New Orleans. A post-hoc analysis from the GATHER1 and GATHER2